Vitamin D deficiency and the seasonality of influenza: what science says

The problem: seasonality and epidemiological unknowns of influenza

Human influenza shows marked seasonality in many temperate areas, with annual winter peaks, and epidemic behaviors that seem to vary in intensity and timing between countries and years. The reasons for seasonality are complex: environmental factors (temperature, humidity), behavioral factors (more time spent indoors), virological factors (antigenic variability), and immunological factors contribute in an integrated way. It is correct to say that there is no single definitive explanation and that many questions remain open regarding the dynamics of influenza epidemics at a population scale.

Among historical hypotheses is that of a "seasonal stimulus" that modifies collective susceptibility and transmission; a possible component of this stimulus is the seasonal variation of circulating vitamin D, linked to sun exposure. It should be emphasized that this hypothesis is plausible and epidemiological: vitamin D deficiency can contribute to individual vulnerability and, in aggregate, to the seasonal profile of respiratory infections, but it alone does not explain all epidemiological observations.

In terms of transmission, concepts such as incubation period and serial interval are useful for understanding chains of contagion; in influenza practice, the variability of transmission pathways, the presence of paucisymptomatic infections, and different social contexts make the application of simple models more complex. The literature studying these aspects raises the need to consider multiple factors simultaneously, including biological ones such as vitamin D.

Plausible biological mechanisms: vitamin D and innate immunity

Biological plausibility is a prerequisite for interpreting epidemiological associations. At the cellular level, vitamin D acts through the vitamin D receptor (VDR) and modulates gene expression in immune cells. Molecular studies have shown that the activation of innate receptors (e.g., Toll-like receptors) can induce the intracellular conversion of 25(OH)D into its active form locally and increase the expression of antimicrobial peptides such as cathelicidin, which has antiviral and antibacterial activity [1].

This intracrine pathway explains why systemic 25(OH)D levels can influence the ability of immune cells to generate rapid antimicrobial responses at the infection site [2]. Molecular evidence provides a credible link between vitamin status and respiratory mucosal defense, but it does not automatically imply that correcting the deficiency eliminates seasonal epidemics: the response is modulated by substrate dose, local enzymatic expression, and genetic and environmental factors [2].

Vitamin D and antimicrobial peptides

Part of the observed effect in the laboratory is due to the induction of antimicrobial peptides, molecules that can limit viral replication or facilitate pathogen clearance from the respiratory tract. The regulation of these peptides appears to depend on the presence of 25(OH)D as an available substrate for the intracellular synthesis of the active form of vitamin D [1][2]. These mechanisms offer a biological explanation for the association between low vitamin D levels and an increased risk of respiratory infections, but they do not define the magnitude of the effect in the general population.

Seasonal dynamics and at-risk populations

Vitamin D deficiency is more frequent in conditions of lower sun exposure (winter, high latitudes), in old age, in obesity, in individuals with darker skin, and in those who live or work indoors. These factors may help explain part of the higher incidence of respiratory infections in colder months. However, seasonality is multifactorial: behavioral variables, viral variability, and changes in social contact are co-responsible for the epidemic dynamic.

Clinical evidence: controlled trials and meta-analyses

To assess whether vitamin D supplementation reduces the risk or severity of respiratory infections, randomized trials and observational studies have been conducted. The literature presents heterogeneous results: some randomized studies report reductions in the incidence of respiratory infections in specific populations or with daily dosing regimens, while others show no significant benefits [4][5][6][7].

A meta-analysis of individual data from numerous trials synthesized the available evidence and found an overall protective effect, more evident in individuals with low baseline 25(OH)D levels and with regular administration (daily or weekly) compared to high intermittent doses [3]. This suggests that baseline status and frequency of administration influence the clinical effect.

Selected randomized studies

Among the relevant trials, a study in Japanese schoolchildren showed a reduction in the incidence of influenza A with 1200 IU/day of cholecalciferol compared to placebo [4]. Other trials in young adults (e.g., in military populations) found decreases in some respiratory infections with winter supplementation [5], while studies in healthy adults from other geographical areas reported null or more modest results [6][7]. Overall, the results indicate that the effect is not universal but depends on sample characteristics and treatment.

Meta-analysis and critical synthesis

The meta-analysis of individual data represents the most robust synthesis available to date and indicates an overall benefit of supplementation on the prevention of respiratory infections, with more effective interventions in deficient subjects and with regular dosages [3]. However, the estimates are of modest magnitude and cannot be automatically generalized to all populations or all respiratory infections: the included trials vary in age, dosage, duration, measured outcome, and epidemiological context, elements that weigh on the interpretation.

What it means in practice

For the non-specialist reader: vitamin D is a factor that contributes to immune function, and its deficiency can increase vulnerability to respiratory infections. Supplementing to correct a documented deficiency is a reasonable measure supported by evidence to improve general health; however, supplementation is not a single definitive measure to prevent influenza epidemics. Established interventions such as seasonal vaccination, hand hygiene, the use of protective equipment in at-risk situations, and public health measures remain the pillars of prevention.

If a deficiency is suspected, the doctor may suggest measuring 25-hydroxyvitamin D (25[OH]D) and recommend a supplementation plan appropriate to the baseline level, age, weight, and any clinical conditions. Modality and dosage should be adapted on a case-by-case basis; avoid high self-prescriptions without medical supervision. The choice between daily dosages and intermittent high-load doses can influence efficacy for infection prevention, based on available evidence [3].

Key takeaways

• Vitamin D modulates innate immunity mechanisms that can affect respiratory tract defense.
• Supplementation can reduce the risk of respiratory infections in people with low baseline levels and if administered regularly; the effect is moderate and variable across studies [3][4].
• Vitamin D deficiency is more common in winter and in specific groups (elderly, people with low sun exposure, obesity).
• Supplementation does not replace influenza vaccination or infection control measures.
• Decisions on testing and supplementation should be made with a doctor, based on individual measurements and conditions.

Limitations of the evidence

It is crucial to distinguish between observational associations and causal evidence. Many observational studies show links between low 25(OH)D levels and a higher incidence of respiratory infections, but such associations can be influenced by confounders (general health status, behaviors, sun exposure) and do not prove causality. Randomized trials are more informative, but their heterogeneity (populations, dosages, outcome definitions) limits the generalizability of the results.

Key methodological limitations include: variability in baseline 25(OH)D levels, differences in the duration and frequency of supplementation, outcomes often based on symptoms or non-uniform diagnoses, and scarcity of data for clinically relevant subgroups. The possibility of publication bias and heterogeneity among studies are also elements to consider in the overall evaluation.

Editorial conclusion

Current literature supports the existence of a plausible and partly demonstrated link between vitamin D status and defense against respiratory infections. There is solid experimental evidence and clinical data indicating a benefit, especially in those with 25(OH)D deficiency and when supplementation is administered regularly. However, vitamin D deficiency cannot be solely blamed for influenza seasonality: the dynamics of epidemics are multifactorial. For the public, the most balanced strategy is to correct any deficiencies under medical supervision and continue to follow established prevention measures.